Fidelity Disruptive Medicine ETF Rating $25.94 +0.26 (+1.01%) Closing price 10/8/2025 03:47 PM EasternExtended Trading$25.98 +0.04 (+0.13%) As of 10/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Fidelity Disruptive Medicine ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FMED Aggregate RatingModerate Buy 2.79Holdings in FMED have an aggregate rating of Moderate Buy based on 444 analyst ratings issued in the past year covering 22 companies (59.7% of the portfolio).FMED Aggregate Price Target$25.94High Prediction$25.94Average Prediction$25.94Low Prediction$25.94Holdings in FMED have an aggregate price target of $25.94 and a range of $25.94 to $25.94 covering 22 companies (59.7% of the portfolio).FMED Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy17 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Fidelity Disruptive Medicine ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 22 FMED Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.44%ALNYAlnylam Pharmaceuticals$450.68-1.9%4.04 of 5 stars2.79$448.04 -0.6%29Analyst Forecast5.04%BSXBoston Scientific$96.73+0.9%4.9289 of 5 stars3.00$120.71 24.8%27Analyst Forecast4.12%ARGXargenex$798.94+0.2%3.6639 of 5 stars3.04$802.90 0.5%25Analyst Forecast3.73%PODDInsulet$315.49+0.7%4.6622 of 5 stars2.85$346.83 9.9%20Positive NewsAnalyst Forecast3.52%VEEVVeeva Systems$301.91-1.4%3.9383 of 5 stars2.56$307.58 1.9%25Positive NewsAnalyst UpgradeInsider Trade3.25%DHRDanaher$205.13-1.7%4.9826 of 5 stars2.77$244.60 19.2%22Trending NewsAnalyst Forecast3.11%WAYWaystar$38.56+1.7%4.2141 of 5 stars3.13$45.14 17.1%16Analyst Forecast3.07%EXASExact Sciences$59.32+2.7%4.5056 of 5 stars2.92$69.19 16.6%24Analyst Upgrade2.90%PENPenumbra$258.92+4.0%4.5374 of 5 stars2.89$303.44 17.2%18News CoverageAnalyst Forecast2.68%LEGNLegend Biotech$32.21+2.5%2.5959 of 5 stars2.73$69.50 115.8%11News CoverageAnalyst Forecast2.64%ISRGIntuitive Surgical$448.09+1.6%4.9536 of 5 stars2.59$589.43 31.5%22Trending NewsAnalyst Forecast2.34%EWEdwards Lifesciences$75.75-1.3%4.8891 of 5 stars2.68$87.06 14.9%25Positive NewsAnalyst UpgradeShort Interest ↓2.20%MASIMasimo$153.72+2.3%4.3533 of 5 stars2.75$194.60 26.6%8Analyst Downgrade2.07%SYKStryker$375.35+1.7%4.9377 of 5 stars2.71$430.10 14.6%21Positive NewsAnalyst Forecast1.94%LFSTLifeStance Health Group$5.64+2.0%3.2061 of 5 stars2.78$8.50 50.7%9Positive NewsAnalyst Upgrade1.80%MRUSMerus$94.380.0%1.0934 of 5 stars2.16$93.12 -1.3%19Analyst Forecast1.77%UNHUnitedHealth Group$369.88+1.7%4.7405 of 5 stars2.44$372.68 0.8%27Trending NewsAnalyst Upgrade1.70%DOCSDoximity$73.62+3.1%2.8599 of 5 stars2.50$69.26 -5.9%22Analyst Forecast1.69%TMOThermo Fisher Scientific$536.21-0.5%4.8905 of 5 stars2.71$590.60 10.1%21Trending NewsAnalyst Forecast1.64%RMDResMed$282.49-0.3%4.5391 of 5 stars2.93$294.20 4.1%15Positive NewsAnalyst Forecast1.55%DXCMDexCom$67.78+2.7%4.9442 of 5 stars2.87$97.42 43.7%23Analyst Forecast1.53%PRVAPrivia Health Group$24.53+2.2%3.7545 of 5 stars2.80$28.42 15.8%15Positive NewsAnalyst Forecast This page (NASDAQ:FMED) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fidelity Disruptive Medicine ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Fidelity Disruptive Medicine ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
